Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3.

PMID:
31481761
2.

The Endless Saga of Monocyte Diversity.

Canè S, Ugel S, Trovato R, Marigo I, De Sanctis F, Sartoris S, Bronte V.

Front Immunol. 2019 Aug 6;10:1786. doi: 10.3389/fimmu.2019.01786. eCollection 2019. Review.

3.

Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells.

Ledo AM, Sasso MS, Bronte V, Marigo I, Boyd BJ, Garcia-Fuentes M, Alonso MJ.

J Control Release. 2019 Feb 10;295:60-73. doi: 10.1016/j.jconrel.2018.12.041. Epub 2018 Dec 26.

PMID:
30593832
4.

Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules.

Lollo G, Matha K, Bocchiardo M, Bejaud J, Marigo I, Virgone-Carlotta A, Dehoux T, Rivière C, Rieu JP, Briançon S, Perrier T, Meyer O, Benoit JP.

J Drug Target. 2019 Jun - Jul;27(5-6):634-645. doi: 10.1080/1061186X.2018.1547733. Epub 2018 Nov 29.

PMID:
30461322
5.

Protamine nanocapsules as carriers for oral peptide delivery.

Thwala LN, Delgado DP, Leone K, Marigo I, Benetti F, Chenlo M, Alvarez CV, Tovar S, Dieguez C, Csaba NS, Alonso MJ.

J Control Release. 2018 Dec 10;291:157-168. doi: 10.1016/j.jconrel.2018.10.022. Epub 2018 Oct 18.

PMID:
30343137
6.

Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo.

Solito S, Pinton L, De Sanctis F, Ugel S, Bronte V, Mandruzzato S, Marigo I.

Curr Protoc Immunol. 2019 Feb;124(1):e61. doi: 10.1002/cpim.61. Epub 2018 Oct 10.

PMID:
30303619
7.

4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells.

Zilio S, Vella JL, De la Fuente AC, Daftarian PM, Weed DT, Kaifer A, Marigo I, Leone K, Bronte V, Serafini P.

J Immunol. 2017 May 15;198(10):4166-4177. doi: 10.4049/jimmunol.1600833. Epub 2017 Apr 10.

8.

Rational design of polyarginine nanocapsules intended to help peptides overcoming intestinal barriers.

Niu Z, Tedesco E, Benetti F, Mabondzo A, Montagner IM, Marigo I, Gonzalez-Touceda D, Tovar S, Diéguez C, Santander-Ortega MJ, Alonso MJ.

J Control Release. 2017 Oct 10;263:4-17. doi: 10.1016/j.jconrel.2017.02.024. Epub 2017 Feb 21.

9.

Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b+ cells that expedite hematopoietic recovery.

Trento C, Marigo I, Pievani A, Galleu A, Dolcetti L, Wang CY, Serafini M, Bronte V, Dazzi F.

Haematologica. 2017 May;102(5):818-825. doi: 10.3324/haematol.2016.155390. Epub 2017 Feb 9.

10.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.

11.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.

12.

Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.

Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, Bronte V, Marigo I, Benoit JP.

Biomaterials. 2016 Jul;96:47-62. doi: 10.1016/j.biomaterials.2016.04.010. Epub 2016 Apr 22.

PMID:
27135716
13.

MDSCs in cancer: Conceiving new prognostic and therapeutic targets.

De Sanctis F, Solito S, Ugel S, Molon B, Bronte V, Marigo I.

Biochim Biophys Acta. 2016 Jan;1865(1):35-48. doi: 10.1016/j.bbcan.2015.08.001. Epub 2015 Aug 6. Review.

PMID:
26255541
14.

Complexity and challenges in defining myeloid-derived suppressor cells.

Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S.

Cytometry B Clin Cytom. 2015 Mar;88(2):77-91. doi: 10.1002/cyto.b.21206. Epub 2014 Dec 12. Review.

15.

Complexity and challenges in defining myeloid-derived suppressor cells.

Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S.

Cytometry B Clin Cytom. 2014 Nov 26. doi: 10.1002/cytob.21206. [Epub ahead of print]

16.

Myeloid-derived suppressor cell heterogeneity in human cancers.

Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V.

Ann N Y Acad Sci. 2014 Jun;1319:47-65. doi: 10.1111/nyas.12469. Review.

PMID:
24965257
17.

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.

Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L.

Cell Death Dis. 2014 Mar 20;5:e1135. doi: 10.1038/cddis.2014.109.

18.

The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.

De Sanctis F, Sandri S, Ferrarini G, Pagliarello I, Sartoris S, Ugel S, Marigo I, Molon B, Bronte V.

Front Immunol. 2014 Feb 24;5:69. doi: 10.3389/fimmu.2014.00069. eCollection 2014. Review.

19.

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A.

Blood. 2014 Jan 30;123(5):697-705. doi: 10.1182/blood-2013-01-478420. Epub 2013 Dec 13.

PMID:
24335499
20.

The immunomodulatory properties of mesenchymal stem cells.

Marigo I, Dazzi F.

Semin Immunopathol. 2011 Nov;33(6):593-602. doi: 10.1007/s00281-011-0267-7. Epub 2011 Apr 19. Review.

PMID:
21499984
21.

Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.

Fernández A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernández LE, Bronte V.

J Immunol. 2011 Jan 1;186(1):264-74. doi: 10.4049/jimmunol.1001465. Epub 2010 Dec 6.

22.

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V.

Immunity. 2010 Jun 25;32(6):790-802. doi: 10.1016/j.immuni.2010.05.010. Epub 2010 Jun 3.

23.

Myeloid-derived suppressor cell heterogeneity and subset definition.

Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V.

Curr Opin Immunol. 2010 Apr;22(2):238-44. doi: 10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. Review.

PMID:
20171075
24.

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.

Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V.

Eur J Immunol. 2010 Jan;40(1):22-35. doi: 10.1002/eji.200939903.

25.

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.

26.

Myeloid-derived suppressor cell role in tumor-related inflammation.

Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V.

Cancer Lett. 2008 Aug 28;267(2):216-25. doi: 10.1016/j.canlet.2008.03.012. Epub 2008 Apr 22. Review.

PMID:
18433992
27.

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V.

Immunol Rev. 2008 Apr;222:162-79. doi: 10.1111/j.1600-065X.2008.00602.x. Review.

PMID:
18364001
28.

Role of arginine metabolism in immunity and immunopathology.

Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, Mantelli B, Bronte V, Zanovello P.

Immunobiology. 2007;212(9-10):795-812. Epub 2007 Nov 14. Review.

PMID:
18086380
29.

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V.

J Clin Invest. 2006 Oct;116(10):2777-90.

30.

Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.

Bronte V, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S, Zanovello P.

Immunol Invest. 2006;35(3-4):327-57. Review.

PMID:
16916757
31.

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A.

J Exp Med. 2005 Apr 18;201(8):1257-68. Epub 2005 Apr 11.

32.

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V.

Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90. Epub 2005 Mar 7.

33.

Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes.

De Palma R, Marigo I, Del Galdo F, De Santo C, Serafini P, Cingarlini S, Tüting T, Lenz J, Basso G, Milan G, Zanovello P, Bronte V.

Cancer Res. 2004 Nov 1;64(21):8068-76.

34.

Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase.

Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P.

J Immunol. 2003 Dec 15;171(12):6396-405.

35.

Derangement of immune responses by myeloid suppressor cells.

Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V.

Cancer Immunol Immunother. 2004 Feb;53(2):64-72. Epub 2003 Oct 30. Review.

PMID:
14593498
36.

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P.

J Immunol. 2003 Jan 1;170(1):270-8.

Supplemental Content

Loading ...
Support Center